Diversified facile synthesis of benzimidazoles, quinazolin-4(3H)-ones and 1,4-benzodiazepine-2,5-diones via palladium-catalyzed transfer hydrogenation/condensation cascade of nitro arenes under microwave irradiation
An efficient methodology for diversified preparation of benzimidazole, quinazolin-4(3H)-ones and 1,4-benzodiazepine-2,5-diones is established using a Pd-CTH/condensation cascade of nitro arenes in a TEA–formic acid mixture under microwave irradiation.
Aminocarbonylations Employing Mo(CO)<sub>6</sub> and a Bridged Two-Vial System: Allowing the Use of Nitro Group Substituted Aryl Iodides and Aryl Bromides
作者:Patrik Nordeman、Luke R. Odell、Mats Larhed
DOI:10.1021/jo302322w
日期:2012.12.21
A bridged two-vial system aminocarbonylation protocol where Mo(CO)6 functions as an external in situ solid source of CO has been developed. For the first time both nitro group containing aryl/heteroaryl iodides and bromides gave good to excellent yields in the Mo(CO)6-mediated and palladium(0)-catalyzed conversion to benzamides, while the identical one-vessel protocol afforded extensive reduction of
Metal and phosgene-free synthesis of 1H-quinazoline-2,4-diones by selenium-catalyzed carbonylation of o-nitrobenzamides
作者:Xiaowei Wu、Zhengkun Yu
DOI:10.1016/j.tetlet.2010.01.040
日期:2010.3
were efficiently synthesized by selenium-catalyzed carbonylation of o-nitrobenzamides under relatively mild conditions. In situ-generated carbonyl selenide (SeCO) is proposed to initiate the catalytic carbonylation. Thus, a concise transition metal and phosgene-free synthetic route to potentially bioactive-substituted 1H-quinazoline-2,4-dione derivatives has been developed.
[EN] BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT<br/>[FR] BENZAMIDES DESTINES AU TRAITEMENT DE TROUBLES NEURO-DEGENERATIFS
申请人:CENTAUR PHARMACEUTICALS, INC.
公开号:WO1996031462A1
公开(公告)日:1996-10-10
(EN) Disclosed are pharmaceutical compositions containing as active ingredient a compound of formula (I) wherein R' is a saturated alkyl of 3 to 5 carbon atoms, each R is independently -NO2 or -NH2 or -NHCOCH3, and n is 1 or 2. Some of these compounds are new. A process for their preparation is also disclosed, as well as their use in the manufacture of medicaments for treating conditions characterised by progressive loss of central nervous system such as Parkinson's disease or Alzheimer's.(FR) Des compositions pharmaceutiques contiennent en guise d'ingrédient actif un composé de formule (I) où R' représente au alkyle saturé doté de 3 à 5 atomes de carbone, R représente indépendemment -NO2, -NH2 ou -NHCOCH3, et n vaut 1 ou 2. Certains de ces composés sont nouveaux. On décrit aussi un procédé permettant de les préparer, ainsi que leur utilisation dans la fabrication de médicaments destinés à traiter des troubles caractérisés par une perte progressive des fonctions du système nerveux central, tels que les maladies de Parkinson ou d'Alzheimer.